Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Zimmer Biomet Holdings's accounts receivables for the quarter that ended in Jun. 2026 was CHF1,414 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
Zimmer Biomet Holdings's Days Sales Outstanding for the quarter that ended in Jun. 2026 was 74.17.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Zimmer Biomet Holdings's Net-Net Working Capital per share for the quarter that ended in Jun. 2026 was CHF-30.27.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Zimmer Biomet Holdings's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Zimmer Biomet Holdings's accounts receivable are only considered to be worth 75% of book value:
Zimmer Biomet Holdings's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Zimmer Biomet Holdings Accounts Receivable Related Terms
Zimmer Biomet Holdings Accounts Receivable Historical Data
* Premium members only.
The historical data trend for Zimmer Biomet Holdings's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Accounts Receivable of CHF1,414 Mil mean?
Zimmer Biomet Holdings (XSWX:ZBH) has a Accounts Receivable of CHF1,414 Mil as of Jun. 2026. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Zimmer Biomet Holdings and its competitors.
Is Zimmer Biomet Holdings' Accounts Receivable too high?
Zimmer Biomet Holdings' current Accounts Receivable is CHF1,414 Mil. Overall, Zimmer Biomet Holdings has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Zimmer Biomet Holdings' Accounts Receivable compare to STE and PEN?
Zimmer Biomet Holdings' Accounts Receivable of CHF1,414 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Medical Devices & Instruments company?
A good Accounts Receivable depends on the Medical Devices & Instruments industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Zimmer Biomet Holdings and its competitors. Zimmer Biomet Holdings's current Accounts Receivable is CHF1,414 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zimmer Biomet Holdings stock overvalued right now?
Zimmer Biomet Holdings (XSWX:ZBH) has a current Accounts Receivable of CHF1,414 Mil. The stock's GF Value™ is CHF101.30, compared to a current price of CHF78.50 — trading 22.5% below its estimated fair value. The current Accounts Receivable is CHF1,414 Mil. Zimmer Biomet Holdings' overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For Zimmer Biomet Holdings (XSWX:ZBH), the current Accounts Receivable is CHF1,414 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zimmer Biomet Holdings (XSWX:ZBH) Overvalued in 2026?
Based on GuruFocus' analysis, Zimmer Biomet Holdings stock appears to be undervalued.
The current stock price of CHF78.50 is trading 22.5% below its estimated GF Value™ of CHF101.30.
Key valuation signals for XSWX:ZBH:
Accounts Receivable: CHF1,414 Mil
GF Value™: CHF101.30 vs. price of CHF78.50 (22.5% below fair value)
No single metric tells the full story. See the XSWX:ZBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
74GF Score
Get the complete analysis for XSWX:ZBH
Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ZBH has been successfully added to your 
